This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ali, Y.M. Articles by Gladman, D.D. Search for Related Content PubMed PubMed Citation Articles by Ali, Y.M. Articles by Gladman, D.D. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Monoclonal gammopathy in systemic lupus erythematosus

Centre for Progrosis Studies, Toronto Hospital Western Division, Toronto, Ontario, Canada

M.B. Urowitz

Centre for Progrosis Studies, Toronto Hospital Western Division, Toronto, Ontario, Canada

D. Ibanez

Centre for Progrosis Studies, Toronto Hospital Western Division, Toronto, Ontario, Canada

D.D. Gladman

Centre for Progrosis Studies, Toronto Hospital Western Division, Toronto, Ontario, Canada, dafna.gladman{at}utoronto.ca

We studied the prevalence, type and associated features of monoclonal gammopathy in patients with systemic lupus erythematosus (SLE). Patients included in the University of Toronto Lupus Database with an abnormal band on serum electropheresis were identified. Monoclonal gammopathy patients were matched with two controls each from the same database by age at SLE diagnosis, sex and disease duration. Of 1083 patients followed at the Lupus Clinic 59 (5.4%) were identified with monoclonal gammopathy. The gammopathies included 32 with IgG, 14 IgM and 12 IgA, one undefined. Nine (15.3%) malignancies were detected in monoclonal gammopathy and 12 (10.1%) in the controls during the entire course of their disease (P = 0.13). None had multiple myeloma. There was no difference between patients with monoclonal gammopathy and their controls with respect to disease activity, damage, or dose of steroids. The mean ESR and gammaglobulin levels in the monoclonal gammopathy patients were higher than the controls at last visit. We conclude that monoclonal gammopathy is more frequent in SLE patients than in the general population and has a benign course in patients with SLE. There were no differences in disease manifestations, treatment approaches, or malignancies between SLE patients with and those without monoclonal gammopathy. Lupus (2007) 16, 426—429.

Key Words: SLE • monoclonal gammopathy • prognosis

Lupus, Vol. 16, No. 6, 426-429 (2007)
DOI: 10.1177/0961203307079045


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J Morel, C Roubille, L Planelles, C Rocha, L Fernandez, C Lukas, M Hahne, and B Combe Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus Ann Rheum Dis, June 1, 2009; 68(6): 997 - 1002. [Abstract] [Full Text] [PDF]